Innopharmax Inc. (InnoPharmax), a subsidiary of Synmosa Biopharma Corporation, which focuses on the development and commercialization of products for the treatment of oncology and specialty. The company’s products include anti-infection agents, contrast agents, oncology agents, and immunological agents. InnoPharmax’s Bestnem product is used to treat the infections caused by susceptible organisms which include lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, or bone and joint infections. The company’s products pipeline includes cardiovascular agents, agents for metabolic disorders, CNS agents, and drugs for rare diseases, among others. Its products find applications in therapeutic areas such as Lymphoma and Parkinson’s disease. InnoPharmax is headquarterd in Taipei, Taiwan.